

**The Milner Therapeutics Symposium:  
 Building Collaborations to Transform Therapies  
 1<sup>st</sup> October 2018  
 West Road Concert Hall**

08:15 – 09:00	Registration
09:00 – 09:15	Welcome – Tony Kouzarides, Milner Institute/Gurdon Institute, University of Cambridge
<b>Session 1</b>	
Chair: Tony Kouzarides	
09:15 – 09:45	Jane Osbourn, MedImmune <i>The Challenges and Opportunities of Biologics</i>
09:45 – 10:15	Emma Rawlins, Gurdon Institute, University of Cambridge <i>Building and Re-building the Lung: Insights from Human Development</i>
10:15 – 10:45	Stephen O’Rahilly, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge <i>The Causes and Consequences of Obesity</i>
10:45 – 11:30	Coffee break
<b>Session 2</b>	
Chair: Jane Osbourn	
11:30 – 12:00	Paul Workman, Institute of Cancer Research <i>Discovering Inhibitors of the HSF1 Pathway for Cancer Treatment – From Phenotypic Screen to Clinical Development Candidate</i>
12:00 – 12:30	Declan Jones, Johnson & Johnson Innovation Centre <i>Tackling the Challenges of Drug Discovery and Development in CNS Disorders – Working with Academia and Biotechs</i>
12:30 – 13:00	Gordon Dougan, Dept. of Medicine, University of Cambridge <i>Bringing Microbial Genomics Closer to the Clinic</i>
13:00 – 14:30	Lunch and poster viewing
<b>Session 3: Breakout sessions: Parallel tracks</b>	
<b>Session 3a: CNS Therapeutics</b>	
Chairs: John Skidmore, The ALBORADA Drug Discovery Institute, University of Cambridge and Declan Jones, Johnson & Johnson Innovation Centre	
14:30 – 14:45	Introduction – Chairs
14:45 – 15:00	Mark Halliday, Dementia Research Institute, University of Cambridge <i>Targeting the Unfolded Protein Response to Treat Neurodegeneration</i>
15:00 – 15:15	Johnny Habchi, Dept of Chemistry, University of Cambridge <i>SAR by Kinetics for Drug Discovery against Alzheimer’s Disease</i>
15:15 – 15:30	Gergely Toth, Cantabio Pharmaceuticals <i>Novel DJ-1 Protein Targeting Small Molecules for the Potential Treatment of Parkinson’s Disease</i>
15:30 – 15:45	Timothy Rooney, The ALBORADA Drug Discovery Institute, University of Cambridge <i>Inhibition of PI3P 4-kinases to Upregulate Autophagy for the Treatment of Neurodegenerative Diseases</i>
15:45 – 16:00	Markus Butz-Ostendorf, Biomax Informatics <i>Knowledge Management in Brain Science with the NeuroXM™ Brain Science Suite</i>
<b>Session 3b: Oncology</b>	
Chairs: Paul Workman, Institute of Cancer Research and Robert Wilkinson, MedImmune	
14:30 – 14:45	Introduction – Chairs

14:45 – 15:00	Mathew Gamett, Wellcome Sanger Institute <i>Functional genomics approaches to identify cancer vulnerabilities</i>
15:00 – 15:15	Duncan Jodrell, CRUK CI, University of Cambridge <i>The Pre-clinical Development of a DNA Damage Response Inhibitor (DDRi) based, Combination Strategy, and its Translation into a Clinical Trial (ATRIUM)</i>
15:15 – 15:30	Chris Smith, CRUK CI, University of Cambridge <i>Towards the Implementation of Circulating Tumour DNA in Oncology (and beyond)</i>
15:30 – 15:45	Rahul Roychoudhuri, The Babraham Institute <i>Molecular Mechanisms of Tolerance and Immunosuppression</i>
15:45 – 16:00	Jeff Roix, NeoPhore Ltd <i>A Novel Small-Molecule Approach to Create New Cancer Neoantigens and Improve Cancer Immunotherapy</i>
<b>Session 3c: Antimicrobial Resistance and the Microbiome</b>	
Chairs: Gordon Dougan, Dept of Medicine, University of Cambridge and Kai Stoeber, Shionogi & Co. Ltd	
14:30 – 14:45	Introduction – Chairs
14:45 – 15:00	David Aanensen, Big Data Institute, University of Oxford/Centre for Genomic Pathogen Surveillance, Wellcome Genome Campus <i>Genomic Surveillance of Antimicrobial Resistance</i>
15:00 – 15:15	Francesca Short, Wellcome Sanger Institute <i>Using Transposon Insertion Sequencing to Understand the Regulation of Virulence and Antimicrobial Resistance in Bacterial Pathogens</i>
15:15 – 15:30	Martin Welch, Dept of Biochemistry, University of Cambridge <i>2C or not 2C; Targeting Short Chain Fatty Acid Catabolism in the Opportunistic Human Pathogen, Pseudomonas Aeruginosa</i>
15:30 – 15:45	Conrad Lichtenstein, Nemesis Bioscience <i>Bacterial Cybergenetics to Resurrect Sensitivity to Antibiotics in Anti-microbial Resistant (AMR) Pathogens</i>
15:45 – 16:00	Trevor Lawley, Wellcome Sanger Institute/Microbiotica <i>The Hygiene Hypothesis and Early Life Microbial Colonization</i>
<b>Session 3d: Technology Platforms and Disease Models</b>	
Chairs: Emma Rawlins, Gurdon Institute, University of Cambridge and David Tough, GlaxoSmithKline	
14:30 – 14:45	Introduction – Chairs
14:45 – 15:00	Carola Morell, Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge <i>Novel approach to model Non-Alcoholic Fatty Liver Disease using human Induced Pluripotent Stem Cells</i>
15:00 – 15:15	Jan Czamecki, Dept of Medical Genetics, University of Cambridge <i>Signal: The Home Page of Mutational Signatures</i>
15:15 – 15:30	Alexander Ross, Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge <i>Utilisation of Human Intestinal Organoids to Study Development and Disease</i>
15:30 – 15:45	Barbara Bernardim, Dept of Chemistry, University of Cambridge <i>Chemically Defined Antibody-drug Conjugates using Carbonylacrylic Reagents</i>
15:45 – 16:00	Jonathan Heeney, Dept of Veterinary Medicine, University of Cambridge <i>Marked Efficacy of Digitally Immune Optimised Synthetic Vaccines (DIOSynVax)</i>
<b>Session 4</b>	
16:30 – 17:00	Round up and close – Kathryn Chapman, The Milner Institute, University of Cambridge
17:00 – 18:30	Drinks and networking